Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIG1 | P18858 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28527519 | 0.84 | LIG1 (0.48) | LIG1HPGDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30118935 | 0.80 | KMT2A (0.58) | LIG1HPGDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8710005 | 0.80 | KMT2A (0.58) | LIG1HPGDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8709073 | 0.80 | KDM4E (0.50) | LIG1HPGDKDM4EALDH1A1SMN1; SMN2 | |
| 2,2'-Dihydroxybenzphenone SCHEMBL29572496 | 0.79 | HPGD (0.67) | LIG1HPGDKDM4EALDH1A1SMN1; SMN2 | |
| 2,2'-Dihydroxybenzphenone SCHEMBL18422 | 0.79 | HPGD (0.67) | LIG1HPGDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8438891 | 0.79 | KDM4E (0.45) | KDM4EALDH1A1SMN1; SMN2HSP90AA1NAPRT | |
| SCHEMBL22426344 | 0.79 | P2RX1 (0.40) | HPGDKDM4EALDH1A1MAPTGAA | |
| SCHEMBL27946157 | 0.78 | MAPT (0.57) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL6767566 | 0.78 | KMT2A (0.57) | HPGDKDM4EALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-3938364-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2022-01-19 | — | — | EP | disclosed |
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | Alterity Therapeutics Limited (AU) | 2021-03-09 | — | — | US | disclosed |
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | Alterity Therapeutics Limited (AU) | 2021-03-09 | — | — | US | disclosed |
| WO-2020186291-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020186291-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-24 | — | — | WO | disclosed |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | SNCA, PARK7, HTT | LIG1 2001/4885HPGD 1462/4885KDM4E 1124/4885 |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | SNCA, HTT, PARK7 | LIG1 2648/4885HPGD 1526/4885KDM4E 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.